Law Firms Seek Lead Plaintiffs in Boston Scientific Securities Case
The outreach follows February disclosures on weak heart‑rhythm sales that drove a sharp drop in the stock.
Overview
- Two plaintiff firms, Rosen and Gross, are inviting BSX investors who bought shares from July 23, 2025 to February 3, 2026 to seek lead‑plaintiff status by May 4, 2026.
- Rosen says a class action is already filed, yet no class is certified and investors are not represented unless they hire counsel or choose to remain absent.
- The complaints allege Boston Scientific misled investors about its U.S. electrophysiology business by touting growth that management knew would not last.
- Shares fell about 17.6% in one day after an early‑February report on weak electrophysiology sales and a lower 2026 outlook that the company tied to slower market growth and tougher competition.
- Electrophysiology covers tools used to map and treat irregular heart rhythms, which is the product line at the center of the lawsuit notices.